How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration

Leukemia

Volumn 16, Issue 10, 2002, Pages 2016-2018

  Meloni, G ^a   Trisolini, S M ^a   Capria, S ^a   Torelli, G F ^a   Baldacci, E ^a   Torromeo, C ^a   Valesini, G ^a   Mandelli, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute myeloid leukemia; Interleukin 2; Toxicity

Indexed keywords

CD3 ANTIGEN; GLAXO IL2; INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2; THYROID HORMONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AFFECTIVE NEUROSIS; ARTICLE; BEHAVIOR DISORDER; BONE MARROW; CANCER RECURRENCE; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; HUMAN; HYPOTHYROIDISM; KIDNEY FUNCTION; LEUKEMIA REMISSION; LIVER FUNCTION; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; T LYMPHOCYTE;

EID: 0036798079     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402566     Document Type: Article

References (13)

1. Ortaldo JR, Mason AT, Gerard JP, Henderson LE, Ferrar W, Hopkins III RF, Herberman BB, Rabin H. Effects of natural and recombinant IL-2 on regulation of IFN production and natural killer activity; lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol 1984; 133: 779-783.
2. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Maory YL, Skibber JM, Shiloni E, Vetto JT, Selpp CA, Simpson C, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukine-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485-1492.
3. Maraninchi D, Blaise D, Viens P, Brandely M, Olive D, Lopez M, Sainty D, Marit G, Stoppa AM, Reiffers J, Gratecos N, Bertau-Perez P, Mannoni P, Mawas C, Hercend T, Sebahoun G, Carcassonne Y. High-dose recombinant interleukin-2 and acute myeloid leukaemias in relapse. Blood 1991, 78: 2182-2187.
4. Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Gavosto F, Mandelli F. Treatment of acute myeloid leukaemia patients with recombinant interleukin-2: a pilot study. Br J Haematol 1991; 77: 491-496.
5. Wiernik PH, Dutcher JP, Todd M, Caliendo G, Benson L. Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. Am J Hematol 1994 47: 41-44.
6. Bergmann L, Heil G, Kolbe K, Lengfelder E, Puzicha E, Martin H, Lohmeyer J, Mitrou PS, Hoelzer D. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. Leuk Lymphoma 1995; 16: 271-279.
7. Mier JW, Aroson FR, Numerof RP, Vachino G, Atkins MB. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathol Immunopathol Res 1988; 7: 459-476.
8. Thomson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, Fefer A. Influence of dose and duration of infusion of Interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988; 6: 669-678.
9. Raab C, Weidmann E, Schmidt A, Bergmann L, Badenhoop K, Usadel KH, Haak T. The effects of interleukin-2 treatment on endothelin and the activation of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol 1999; 50: 37-44.
10. Umeuchi M, Makino T, Arisawa M, Izumi S, Saito S, Nozawa S. The effect of interleukin-2 on the release of gonadotropin and prolactin in vivo and in vitro. Endocr J 1994; 41: 547-551.
11. Klempner MS, Noring R, Mier JW, Atkins MB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 1990; 322: 959-965.
12. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos AG, Mandelli F. Interleukin-2 may induce prolonged remission in advanced acute myelogenous leukemia. Blood 1994; 84: 2158-2163.
13. Meloni G, Vignetti M, Andrizzi C, Capria S, Foa R, Mandelli F. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: update experience with 20 cases. Leuk Lymphoma 1996; 21: 429-435.